

Contents

Preface	xvii
Contributing Authors	xviii
Section I. Toxicology Testing in the Hospital Setting	
Barbarajeane Magnani, Editor	
CHAPTER 1. Introduction and Organizational Aspects of a Hospital Toxicology Laboratory	3
Tai C. Kwong and Barbarajeane Magnani	
Introduction, 3	
Emergency Toxicology, 3	
Toxicology Testing Supporting Other Clinical Services, 3	
On-Site Testing, 4	
Confirmation Testing and Adulterant Testing, 4	
Confirmation Testing, 4	
Urine Adulterant Testing, 5	
Medical-Legal Testing, 5	
Clinical Testing with Legal Implications, 5	
Legal Testing, 5	
Summary, 6	
CHAPTER 2. Supporting the Emergency Department	7
Barbarajeane Magnani and Tai C. Kwong	
Introduction, 7	
Tier 1 Tests, 7	
Quantitative Serum Tests, 8	
Urine Qualitative Tests, 9	
Tier 2 Tests, 9	
Unique Challenges Associated with Testing in the ED, 10	
Toxidromes, 12	
CHAPTER 3. Supporting the Pain Service	15
Catherine A. Hammett-Stabler and Barbarajeane Magnani	
Introduction, 15	
Role of the Clinical Laboratory in Pain Management, 16	
Samples, Analytes, and Methods, 17	
Clinical Pathology Consultations, 21	
Alternate Specimens and Issues, 24	
Summary and Conclusions, 24	

CHAPTER 4. Biomonitoring of Medical Professional Substance Abuse: Practical and Analytical Issues.....27

Robert A. Middleberg

Introduction, 27

Treatment and Monitoring of Impaired Medical Professionals, 27

 Oversight, 27

 Treatment Monitoring, 28

Substances Commonly Abused by Medical Professionals, 28

Analytical Considerations of Medical Professional Testing, 28

 General, 28

 Preanalytical Considerations, 29

 Analyses, 30

 Scope of Testing, 30

 Screening, 30

 Confirmation Testing, 31

 Interpretive Issues, 31

Summary, 32

CHAPTER 5. Workplace Drug Testing and the Role of the Medical Review Officer.....33

Michael G. Bissell

Introduction, 33

Workplace Drug Testing, 33

 The Medical Review Officer, 34

Positivity Criteria and Sources of Legitimate Medical Explanations for HHS 5 Urine Tests, 35

 Amphetamines, 35

 Amphetamine, 35

 Methamphetamine, 35

 Cocaine, 36

 Marijuana, 36

 Opiates, 36

 Heroin, 37

 Morphine, 37

 Codeine, 37

 Opiate Identification, 37

 Phencyclidine, 37

Medical Review Officer Review of Specimen Validity Testing, 38

 Definitions of Specimen Validity Testing Results and Associated Medical Review Officer Actions, 38

 Negative or Positive Specimen, 38

 Negative Dilute Specimen, 38

 Positive Dilute Specimen, 38

 Substituted Specimen, 38

 Adulterated Specimen, 38

 Invalid Drug Test, 39

Summary, 39

CHAPTER 6. The Hospital Autopsy and Toxicology Testing.....41

D. Kimberley Molina and Barbarajean Magnani

Introduction, 41

The Autopsy, 41

Specimen Collection, 42

Specimen Selection, 44

Ordering Toxicology Testing, 44

Interpretation of Toxicology Results, 45

Medicolegal Issues, 46

Summary, 47

CHAPTER 7. Regulatory Issues of Toxicology Laboratory Operations 49

Wayne R. Markus

Introduction, 49

CLIA Certification, 49

 CLIA Certificates, 49

CLIA-Exempt Laboratories, 50

State Exemption from CLIA, 50

Forensic Testing Accreditation, 50

 The CAP FDT Accreditation Program, 50

 Forensic Testing in the Clinical Laboratory, 51

Medical Testing with Legal Implications, 51

Waived Tests, 51

Nonprofit Agencies with Deemed Status to Accredite Laboratories, 51

Five Condition Level Requirements for Accreditation, 52

 First Condition Level Requirement: Proficiency Testing, 52

 Second Condition Level Requirement: Facility Administration, 52

 Third Condition Level Requirement: Quality Systems, 53

 Quality Assurance (Assessment)/Quality Management, 53

 Proficiency Testing and Alternative Performance Assessment, 54

 Evaluation of Proficiency Testing and Alternative Performance Assessment, 54

 Method Validation, 54

 Fourth Condition Level Requirement: Personnel, 56

 Competency Evaluation of Technical Staff, 57

 Fifth Condition Level Requirement: Inspection, 57

ISO 15189, 57

Alcohol and Volatiles Proficiency Testing, 57

Immunoassay Urine Drug Screen Proficiency Testing, 57

Broad-Spectrum Urine Drug Screen Proficiency Testing, 58

Whole Blood, Serum, and Plasma Drug Screen Proficiency Testing, 59

Urine Adulteration Proficiency Testing, 59

Summary, 59

CHAPTER 8. Adverse Drug Events, Poisonings, and Abuse 61

Daniel J. Cobaugh

Introduction, 61

Experience Across the Continuum of Care, 62

Identifying the Point of Occurrence of Adverse Drug Events, 64

Medications Frequently Implicated in Adverse Drug Events, 64

System Failures Versus “Bad Apples,” 65

Poisonings, 66

Drug Abuse and Misuse, 66

Conclusions, 67

Section II. Methodologies for the Toxicology Laboratory

Tai C. Kwong, Editor

CHAPTER 9. Alternate Specimens for Drugs-of-Abuse Testing:

Preanalytical and Interpretative Considerations 71

Uttam Garg and Angela M. Feguson

Introduction, 71

Hair, 71

 Preanalytical and Interpretive Considerations in Drug Testing of Hair Samples, 73

 Environmental or External Contamination, 73

 Hair Color and Drug Incorporation, 74

 Adulteration Issues, 75

Oral Fluid, 75	
Preanalytical and Interpretative Considerations in Drug Testing of Oral Fluid Samples, 76	
Sample Collection, 76	
Correlation of Drug Concentrations and Positivity Rate Between Saliva and Urine or Blood, 77	
Sample Adulteration Issues, 77	
Sweat, 77	
Preanalytical and Interpretative Considerations in Drug Testing of Sweat Samples, 78	
Sample Collection, 78	
Drug Detection in Sweat and Its Relationship to Urine Testing, 78	
Sample Adulteration and Contamination Issues, 78	
Meconium, 79	
Other Alternative Samples for Drug Testing, 79	
Summary, 79	
CHAPTER 10. Analytical Methodologies for the Toxicology Laboratory	83
Petrie M. Rainey and Geoffrey S. Baird	
Introduction, 83	
Spot Tests, 83	
Spectrometry, 83	
Direct Spectrometry, 83	
Atomic Absorption Spectrometry, 84	
Spectrochemistry, 84	
Immunoassays, 84	
Chromatography, 87	
Thin Layer Chromatography, 88	
High Performance Liquid Chromatography, 88	
Gas Chromatography, 89	
Mass Spectrometry, 90	
Ionization Techniques, 90	
Separation of Ions, 91	
Ion Detection, 93	

Section IIIA. The Toxicology Laboratory's Test Menu: Abused Substances

Michael G. Bissell, Editor

CHAPTER 11. Ethanol	97
Graham R. Jones	
Descriptive Chemistry, 97	
Pharmacology, 97	
Type of Agent, 97	
Context of Human Use, 97	
Abuse Potential and Characteristics, 97	
Adverse Effects, 97	
Overdose and Toxicity, 98	
Toxic Dose, 98	
Pharmacokinetics, Metabolism, and Excretion, 98	
Pharmacokinetics, 98	
Metabolism and Excretion, 98	
Analysis, 98	
Analytical Parameters, 98	
Specimen Types, Requirements, and Characteristics, 99	
Plasma/Serum Versus Blood, 99	
Urine, 99	
Postmortem Considerations, 99	
Analysis of Vitreous Fluid, 99	
Other Specimens, 99	

Modes of Analysis, 100	
Colorimetric, 100	
Enzymatic, 100	
Gas Chromatography, 100	
Known Analytical Issues and Problems, 100	
Clinical Issues, 101	
Clinical Interpretation of Analytical Findings, 101	
Back-Extrapolation of Blood Alcohol Concentration, 101	
Estimation of Dose, 101	
Other Sources of Alcohol, 102	
Treatment and Rehabilitation for Overdose and Toxicity, 102	
CHAPTER 12. Cannabis	104
Michael G. Bissell	
Descriptive Chemistry, 104	
Δ^9 -tetrahydrocannabinol, 104	
Δ^8 -tetrahydrocannabinol, 104	
Cannabinol, 104	
Cannabidiol, 105	
Δ^9 -tetrahydrocannabinolic acid, 105	
Origin, 105	
Pharmacology, 105	
Type of Agent, 105	
Context of Human Use, 105	
Abuse Potential and Characteristics, 106	
Overdose and Toxicity, 106	
Adverse Effects and Complications, 107	
Central Nervous System, 107	
Cardiovascular, 107	
Respiratory, 107	
Reproductive, 107	
Toxic Dose, 108	
Pharmacokinetics, Metabolism, and Excretion, 108	
Pharmacokinetics, 108	
Metabolism, 108	
Excretion, 109	
Volume of Distribution, 109	
Half-Life, 109	
Analysis, 109	
Analytical Parameters, 109	
Specimen Types, Requirements, and Characteristics, 109	
Modes of Analysis, 110	
Known Analytical Issues and Problems, 110	
Clinical Issues, 110	
Clinical Interpretation of Analytical Findings, 110	
Treatment and Rehabilitation for Overdose and Toxicity, 110	
CHAPTER 13. Cocaine	112
Michael G. Bissell	
Descriptive Chemistry, 112	
Cocaine, 112	
Cocaine Hydrochloride, 112	
Origin, 112	
Pharmacology, 112	
Type of Agent, 112	
Context of Human Use, 112	

Intoxication and Abuse, 113	
Overdose and Toxicity, 114	
Adverse Effects and Complications, 114	
Central Nervous System, 114	
Cardiovascular, 114	
Respiratory, 115	
Musculoskeletal and Renal, 115	
Sexual, 115	
Pregnancy, 115	
Breast-feeding, 115	
Toxic Dose, 115	
Pharmacokinetics, Metabolism, and Excretion, 116	
Pharmacokinetics, 116	
Metabolism, 116	
Excretion, 117	
Analysis, 117	
Analytical Parameters, 117	
Specimen Types, Requirements, and Characteristics, 117	
Modes of Analysis, 117	
Known Analytical Issues and Problems, 117	
Clinical Issues, 118	
Clinical Interpretation of Analytical Findings, 118	
Treatment of Acute Overdose, 118	
CHAPTER 14. Amphetamines	119
Marion L. Snyder and Stacy Eugenie Melanson	
Descriptive Chemistry, 119	
Amphetamine, 119	
Methamphetamine, 119	
Origin, 119	
Pharmacology, 120	
Type of Agent, 120	
Context of Human Use, 120	
Abuse Potential and Characteristics, 120	
Overdose and Toxicity, 120	
Complications, 120	
Toxic Dose, 120	
Pharmacokinetics, Metabolism, and Excretion, 120	
Pharmacokinetics, 120	
Metabolism and Excretion, 121	
Analysis, 121	
Clinical Issues, 123	
Clinical Interpretation of Analytical Findings, 123	
Treatment of Overdose and Toxicity, 124	
CHAPTER 15. Barbiturates	126
Marion L. Snyder and Stacy Eugenie Melanson	
Descriptive Chemistry, 126	
Amobarbital, 126	
Butalbital, 126	
Butobarbital, 126	
Mephobarbital, 127	
Pentobarbital, 127	
Phenobarbital, 127	
Secobarbital, 127	
Thiopental, 127	

Origin, 127	
Pharmacology, 127	
Type of Agent, 127	
Context of Human Use, 128	
Abuse Potential and Characteristics, 128	
Overdose and Toxicity, 128	
Complications, 128	
Toxic Dose, 128	
Pharmacokinetics, Metabolism, and Excretion, 128	
Pharmacokinetics, 128	
Metabolism and Excretion, 130	
Analysis, 130	
Clinical Issues, 131	
Clinical Interpretation of Analytical Findings, 131	
Treatment of Overdose and Toxicity, 131	
CHAPTER 16. Benzodiazepines	132
Marion L. Snyder and Stacy Eugenie Melanson	
Descriptive Chemistry, 132	
Alprazolam, 132	
Diazepam, 132	
Nordiazepam, 132	
Lorazepam, 133	
Oxazepam, 133	
Chlordiazepoxide, 133	
Triazolam, 133	
Flurazepam, 133	
Flunitrazepam, 134	
Clonazepam, 134	
Origin, 134	
Pharmacology, 134	
Type of Agent, 134	
Context of Human Use, 134	
Abuse Potential and Characteristics, 134	
Overdose and Toxicity, 135	
Toxic Dose, 135	
Pharmacokinetics, Metabolism, and Excretion, 135	
Pharmacokinetics, 135	
Metabolism and Excretion, 135	
Analysis, 135	
Clinical Issues, 138	
Clinical Interpretation of Analytical Findings, 138	
Treatment of Overdose and Toxicity, 138	
CHAPTER 17. Opioids 1: Opiates	140
Michael G. Bissell and Michael A. Peat	
Descriptive Chemistry, 140	
Morphine, 140	
Codeine, 140	
Thebaine, 141	
Heroin, 141	
Hydromorphone, 141	
Hydrocodone, 141	
Oxymorphone, 141	
Oxycodone, 142	
Origin, 142	

Pharmacology, 142	
Type of Agent, 142	
Context of Human Use, 143	
Abuse Potential and Characteristics, 143	
Overdose and Toxicity, 143	
Adverse Effects and Complications, 144	
Cardiovascular, 144	
Respiratory, 144	
Renal, 144	
Metabolic, 144	
Immune, 144	
Reproductive, 144	
Toxic Dose, 144	
Pharmacokinetics, Metabolism, and Excretion, 144	
Pharmacokinetics, 144	
Metabolism, 145	
Excretion, 145	
Analysis, 146	
Specimen Types, Requirements, and Characteristics, 146	
Modes of Analysis, 146	
Known Analytical Issues and Problems, 147	
Clinical Issues, 147	
Clinical Interpretation of Analytical Findings, 147	
Treatment and Rehabilitation, 147	
CHAPTER 18. Opioids 2: Synthetic Opioids.....	149
Hoi-Ying Elsie Yu	
Descriptive Chemistry, 149	
Fentanyl, 149	
Meperidine, 149	
Propoxyphene, 149	
Tramadol, 150	
Origin, 150	
Pharmacology, 150	
Type of Agent, 150	
Context of Human Use, 150	
Abuse Potential and Characteristics, 151	
Overdose and Toxicity, 151	
Drug and Disease Interactions, 152	
Toxic Dose, 152	
Pharmacokinetics, Metabolism, and Excretion, 152	
Pharmacokinetics, 152	
Metabolism and Excretion, 153	
Analysis, 153	
Specimen Types, Requirements, and Characteristics, 153	
Modes of Analysis, 153	
Known Analytical Issues and Problems, 154	
Clinical Issues, 154	
Clinical Interpretation of Analytical Findings, 154	
Treatment and Rehabilitation, 154	
CHAPTER 19. Opioids 3: Synthetic Opioids Continued (Methadone and Buprenorphine).....	157
Glynnis B. Ingall and Bharathi Vennapusa	
Descriptive Chemistry, 157	
Methadone, 157	
Buprenorphine, 157	
Origin, 157	

Pharmacology, 158	
Type of Agent, 158	
Context of Human Use, 158	
Abuse Potential and Characteristics, 158	
Overdose and Toxicity, 159	
Toxic Dose, 160	
Pharmacokinetics, Metabolism, and Excretion, 160	
Pharmacokinetics, 160	
Metabolism, 160	
Excretion, 161	
Analysis, 161	
Specimen Types, Requirements, and Characteristics, 161	
Modes of Analysis, 161	
Known Analytical Issues and Problems, 161	
Clinical Issues, 162	
Clinical Interpretation of Analytical Findings, 162	
Treatment and Rehabilitation, 162	
CHAPTER 20. Phencyclidine	164
Donald L. Frederick	
Descriptive Chemistry, 164	
Origin, 164	
Pharmacology, 164	
Type of Agent, 164	
Context of Human Use, 164	
Abuse Potential and Characteristics, 165	
Overdose and Toxicity, 165	
Toxic Dose, 165	
Pharmacokinetics, Metabolism, and Excretion, 165	
Pharmacokinetics, 165	
Metabolism, 165	
Excretion, 166	
Analysis, 166	
Specimen Types, Requirements, and Characteristics, 166	
Modes of Analysis, 166	
Known Analytical Issues and Problems, 166	
Clinical Issues, 166	
Clinical Interpretation of Analytical Findings, 166	
Treatment and Rehabilitation, 166	
CHAPTER 21. Club Drugs (GHB, DXM, MDMA)	168
Donald L. Frederick	
Descriptive Chemistry, 168	
Gamma-Hydroxybutyric Acid (GHB), 168	
Dextromethorphan (DXM), 168	
Methylenedioxymethamphetamine (MDMA), 168	
Origin, 169	
Pharmacology, 169	
Type of Agent, 169	
Context of Human Use, 169	
Abuse Potential and Characteristics, 170	
Overdose and Toxicity, 170	
Toxic Dose, 171	
Pharmacokinetics, Metabolism, and Excretion, 171	
Pharmacokinetics, 171	
Metabolism, 171	
Excretion, 172	

Analysis, 172
 Specimen Types, Requirements, and Characteristics, 172
 Modes of Analysis, 172
 Clinical Issues, 173
 Clinical Interpretation of Analytical Findings, 173
 Treatment and Rehabilitation, 173

Section IIIB. The Toxicology Laboratory’s Test Menu: Toxic Substances and Overdoses

Michael G. Bissell, Editor

CHAPTER 22. Over-the-Counter Analgesics 179

Hoi-Ying Elsie Yu and Barbarajean Magnani

Introduction, 179
 Descriptive Chemistry, 179
 Salicylate, 179
 Acetaminophen, 179
 Origin, 179
 Salicylate, 179
 Acetaminophen, 179
 Pharmacology, 180
 Type of Agent, 180
 Context of Human Use, 180
 Overdose and Toxicity, 180
 Salicylate, 180
 Acetaminophen, 181
 Pharmacokinetics, Metabolism, and Excretion, 182
 Pharmacokinetics, 182
 Metabolism and Excretion, 182
 Analysis, 183
 Specimen Types, Requirements, and Characteristics, 183
 Modes of Analysis, 183
 Salicylate, 183
 Acetaminophen, 183
 Known Analytical Issues and Problems, 184
 Salicylate, 184
 Acetaminophen, 184
 Clinical Issues, 184
 Clinical Interpretation of Analytical Findings, 184
 Salicylate, 184
 Acetaminophen, 184
 Treatment and Rehabilitation, 185
 Salicylate, 185
 Acetaminophen, 185
 General Considerations for Patients with Potential Analgesic Toxicity, 185

CHAPTER 23. Non-Ethanol Volatiles and Ethylene Glycol 188

Michael G. Bissell

Descriptive Chemistry, 188
 Acetone, 188
 Methanol, 188
 Isopropanol, 188
 Ethylene Glycol, 188
 Pharmacology, 188
 Context of Human Use, 189
 Exposure, 189
 Airborne and Workplace Exposure: Hazardous Material (Hazmat) Considerations, 189
 Exposure by Ingestion: Epidemiology, 189

Pharmacokinetics, Metabolism, and Excretion, 190	
Pharmacokinetics, 190	
Metabolism and Excretion, 190	
Toxicity, 191	
Acetone, 191	
Methanol, 191	
Isopropanol, 192	
Ethylene Glycol, 192	
Analysis, 192	
Specimen Types, Requirements, and Characteristics, 192	
Modes of Analysis, 192	
Known Analytical Issues and Problems, 193	
Clinical Issues, 193	
Clinical Interpretation of Analytical Findings, 193	
Acetone and Isopropanol, 193	
Methanol and Ethylene Glycol, 193	
Treatment and Management, 194	
Acetone, 194	
Isopropanol, 194	
Methanol, 194	
Ethylene Glycol, 195	
CHAPTER 24. Lead and Other Toxic Metals.....	196
Robert A. Middleberg	
Introduction, 196	
Descriptive Chemistry, 196	
Lead, 196	
Arsenic, 196	
Cadmium, 196	
Mercury, 196	
Thallium, 196	
Pharmacology, 196	
History and Context of Human Use, 196	
Lead, 196	
Arsenic, 197	
Cadmium, 197	
Mercury, 197	
Thallium, 197	
Exposure, 197	
Lead, 197	
Arsenic, 198	
Cadmium, 198	
Mercury, 198	
Thallium, 198	
Toxicokinetics, Metabolism, and Excretion, 199	
Lead, 199	
Arsenic, 199	
Cadmium, 199	
Mercury, 200	
Thallium, 200	
Toxicity, 200	
Lead, 200	
Arsenic, 202	
Cadmium, 202	
Mercury, 203	
Thallium, 203	

Analysis, 203	
Specimen Types, Requirements, and Characteristics, 203	
Lead, 203	
Arsenic, 204	
Cadmium, 204	
Mercury, 204	
Thallium, 204	
Modes of Analysis, 204	
Lead, 204	
Arsenic, 204	
Cadmium, 204	
Mercury, 204	
Thallium, 204	
Known Analytical Issues and Problems, 204	
Lead, 204	
Cadmium, 204	
Mercury, 204	
Clinical Issues, 205	
Clinical Interpretation of Analytical Findings, 205	
Treatment and Management, 205	
Lead, 205	
Arsenic, 205	
Cadmium, 206	
Mercury, 206	
Thallium, 206	
CHAPTER 25. Common Household and Environmental Toxins	
(Carbon Monoxide, Cyanide, Organophosphates, Warfarins)	208
Leland B. Baskin	
Introduction, 208	
Descriptive Chemistry, 208	
Carbon Monoxide, 208	
Hydrogen Cyanide, 208	
Organophosphates, 208	
Parathion, 208	
Warfarins, 209	
Warfarin, 209	
Dicoumarol, 209	
Pharmacology, 209	
History and Context of Human Exposure, 209	
Carbon Monoxide, 209	
Cyanide, 209	
Organophosphates, 209	
Warfarins, 210	
Toxicokinetics, Metabolism, and Excretion, 210	
Carbon Monoxide, 210	
Cyanide, 210	
Organophosphates, 210	
Warfarins, 210	
Toxicity, 211	
Carbon Monoxide, 211	
Cyanide, 212	
Organophosphates, 212	
Warfarins, 213	
Toxic Dose, 213	
Carbon Monoxide, 213	

- Cyanide, 213
- Organophosphates, 213
- Analysis, 213
 - Specimen Types and Requirements, 213
 - Carbon Monoxide, 213
 - Cyanide, 213
 - Organophosphates, 213
 - Modes of Analysis, 213
 - Carbon Monoxide, 213
 - Cyanide, 214
 - Organophosphates, 214
 - Warfarins, 214
 - Known Analytical Problems, 214
 - Carbon Monoxide, 214
 - Organophosphates, 214
- Clinical Issues, 214
 - Clinical Interpretation of Analytical Findings, 214
 - Carbon Monoxide, 214
 - Cyanide, 215
 - Organophosphates, 215
 - Warfarins, 215
 - Treatment, 215
 - Carbon Monoxide, 215
 - Cyanide, 215
 - Organophosphates, 216
 - Warfarins, 216

Section IV. Drug Disposition, Toxicokinetics, and Individualization

Alan H.B. Wu, Editor

CHAPTER 26. Pharmacokinetic Concepts for Toxicology and Therapeutic Drug Monitoring 221

Yashpal Agrawal

- Introduction, 221
- Pharmacokinetics and Pharmacodynamics, 221
- Drug Absorption, 221
- Bioavailability, 221
- First-Pass Metabolism, 222
- Drug Distribution, 222
- Key Pharmacokinetic Parameters and Concepts, 222
 - Volume of Distribution, 222
 - Drug Elimination, 223
 - Clearance, 223
 - Elimination Rate Constant, 224
 - Compartmental Models of Pharmacokinetics, 225
 - One-Compartment Model, 225
 - Two-Compartment Model, 225
 - Half-Life, 225
 - Concept of Steady State, 226
 - Area Under the Curve, 227

CHAPTER 27. Clinical Usefulness of Monitoring Free (Unbound) Concentrations of Therapeutic Drugs 228

Amitava Dasgupta

- Introduction, 228
- Candidates for Free Drug Monitoring, 229

Monitoring Concentrations of Free Anticonvulsants, 229	
Rationale for Monitoring Free Phenytoin Concentration, 229	
Rationale for Monitoring Free Valproic Acid Concentration, 231	
Rationale for Monitoring Free Carbamazepine Concentration, 231	
When Should Free Anticonvulsant Be Monitored?, 232	
Elevated Free Anticonvulsant Concentrations in Uremia, 232	
Elevated Free Anticonvulsant Levels in Hepatic Disease, 232	
Free Anticonvulsant Concentrations in Patients with AIDS, 233	
Free Anticonvulsants in Pregnancy, 233	
Drug–Drug Interactions and Elevated Free Anticonvulsant Concentrations, 233	
Is Free Monitoring Needed for Any New Anticonvulsant?, 234	
Rationale for Free Drug Monitoring of Drugs Bound to Alpha-1-Acid Glycoprotein, 234	
Rationale for Monitoring Free Concentrations of Immunosuppressant Drugs, 235	
Rationale for Monitoring Free Concentrations of Protease Inhibitors, 235	
Monitoring Free Digoxin Concentration, 236	
Saliva and Tears: Alternatives to Serum, 236	
Assay Techniques for Free Anticonvulsants, 237	
Conclusions, 237	
CHAPTER 28. Pharmacogenomic Testing and the Future of Hospital Toxicology	241
Alan H.B. Wu	
Introduction, 241	
Definitions and Terminology, 241	
Reviews and Tools for Pharmacogenomics, 242	
Drivers of Clinical Pharmacogenomics, 242	
Pharmacogenomic Testing for Therapeutic Efficacy and Toxicity Avoidance, 242	
CYP2C9 and VKORC1 for Warfarin, 242	
CYP2D6 for Tamoxifen, 244	
UGT1A1 for Irinotecan, 244	
CYP2C19 for Clopidogrel, 244	
TPMT for Thiopurine Drugs, 245	
HLA-B Testing to Prevent Delayed Hypersensitivity Reactions, 245	
Summary, 246	
Section V. Appendices: Templates and FAQs	
Tai C. Kwong, Editor	
APPENDIX A. Urine Toxic Screen Template	251
Barbara Jean Magnani	
APPENDIX B. Serum Toxic Screen Template	255
Barbara Jean Magnani	
APPENDIX C. Therapeutic Drug Monitoring Template	261
Barbara Jean Magnani	
APPENDIX D. Frequently Asked Questions on Clinical Urine Drugs-of-Abuse Testing	271
Tai C. Kwong	
Index	276